Cargando…

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study

BACKGROUND: Osilodrostat, a potent cortisol synthesis inhibitor, demonstrated safety and efficacy in the treatment of Cushing's disease (CD). No information is available describing use of osilodrostat in non-pituitary Cushing's syndrome (CS) in US patients. Data from a real-world study in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auchus, Richard Joseph, Fleseriu, Maria, Huang, Wenyu, Spencer-Segal, Joanna L, Yuen, Kevin Choong Ji, Dacus, Kelley C, Ludlam, William Henry, Babler, Elizabeth Kay, Das, Ashis K, Campos, Cynthia, Broder, Michael S, Ioachimescu, Adriana Gabriela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627142/ http://dx.doi.org/10.1210/jendso/bvac150.982

Ejemplares similares

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

LBMON174 Germline Molecular Genetics Of Pituitary Adenomas
por: Alzahrani, Ali, et al.
Publicado: (2022)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

LBMON138 Leg Tumeo: Is It Neuroendocrine Tumor?
por: Priyadarshini, Shista, et al.
Publicado: (2022)

LBMON137 Don't Be Fooled By Normotension Pheo Could Be The Potential
por: Idriss, Setana, et al.
Publicado: (2022)

LBMON135 Diffuse Large B-cell Lymphoma Affecting The Pituitary Gland: A Case Report
por: Masumy, Misha, et al.
Publicado: (2022)

LBMON141 Macroorchidism In A Patient With A Functional Gonadotroph Macroadenoma
por: Chale-Matsau, Bettina, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function
por: Minasyan, Mari, et al.
Publicado: (2023)

LBMON172 Impact Of Photoperiodic Green Light During Incubation On Change Hormone In The Embryo Of Chicken
por: Abdulateef, Salwan, et al.
Publicado: (2022)

LBMON173 Non-functioning Seller Masses: Tumor Types, Surgical Management And Course Over Time
por: Alhadlaq, Omar, et al.
Publicado: (2022)

LBMON140 Central Diabetes Insipidus Manifesting After Vasopressin Withdrawal In A Critically Ill Patient
por: Patel, Toral, et al.
Publicado: (2022)

SUN-LB074 Racial Distribution, Presentation and Outcome in Acromegaly and Cushing's Disease: A Tertiary Referral Center Study in 220 Patients
por: Goswami, Neevedita, et al.
Publicado: (2019)

LBMON139 A Case of Adipsic Diabetes Insipidus In Patient With Third Ventricular Tumor And Right Frontal Craniotomy.
por: Thambuluru, Sirisha Reddy, et al.
Publicado: (2022)

LBMON175 Nadir Growth Hormone Concentrations In Patients With Acromegaly Relate To Disease Activity, Glucose Metabolism, BMI And Sex
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2022)

LBMON114 Enrichment Of Rare Sequence Variants In Genes That Communicate Metabolic Signals To The GnRH System In Hypothalamic Amenorrhea
por: Brown, Ethan, et al.
Publicado: (2022)

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)
por: Auchus, Richard, et al.
Publicado: (2019)

LBMON62 Central Diabetes Insipidus From A Patients’ Perspective- From Management To Psychological Co-morbidities And Re-naming Of The Condition
por: Atila, Cihan, et al.
Publicado: (2022)

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

LBMON134 Igg4 Related Hypophysitis And Skull Base Lesion: Retrospective Analysis Of 10 Years’ Experience Of A Tertiary Care Hospital Of Northern India.
por: Chakraborty, Ananda Mohan, et al.
Publicado: (2022)

SAT-300 Evading Death: Noxa in Cushing’s Disease Pituitary Adenomas
por: Alvarez, Reinier, et al.
Publicado: (2020)

SAT-248 Cushing’s Disease with Two ACTH-Producing Pituitary Tumors
por: Mathai, Christine, et al.
Publicado: (2020)

Canine Pituitary Organoids as 3D In Vitro Model for Cushing Disease
por: Sanders, Karin, et al.
Publicado: (2021)

THU009 Subclinical Cushing’s Syndrome In An ACTH-secreting Pituitary Macroadenoma
por: Akabogu, Nwamaka Gloria, et al.
Publicado: (2023)

OR20-05 Generation Of CDH23-mutated Pituitary Neuroendocrine Tumor Organoids From Induced Pluripotent Stem Cells To Model Cushing’s Disease Pathogenesis
por: Chakrabarti, Jayati, et al.
Publicado: (2023)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

MON-405 Cushing's Disease: An Oligosymptomatic Patient with ACTH-Secreting Pituitary Macroadenoma
por: Manrique Franco, Katty, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tsm0qcdtsbnm0u80dsic889313